As per reports, Columbia has signed an agreement with Janssen, Johnson & Johnson’s (JNJ) pharmaceutical division to acquire 9 million doses of coronavirus vaccines.
Columbia with over 1.6 million cases of coronavirus and 43,000 deaths, had earlier secured deals with Pfizer and AstraZeneca Plc to provide 10 million doses each of their COVID-19 vaccines in addition to 20 million doses through the COVAX mechanism.
“Today the agreement was signed for the acquisition of 9 million vaccines for 9 million citizens,” stated President Ivan Duque.
Duque informed that earlier-secured vaccines require two doses per person, but the J&J vaccines need just one, enough for around 29 million population. He also informed that more vaccine agreements will be finalized in the coming days allowing for the vaccination of 35 million people in the country. The country will provide COVID-19 vaccines for free under its national vaccination plan, but people will also be allowed to purchase them privately.
First, the vaccination will be for healthcare workers and those over 80 years of age, followed by people aged 60 and 79, followed by those suffering from chronic health conditions, as they are more vulnerable to Covid-19.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.